. Administration of dietary fiber and/or exogenous SCFAs alter gut butyrate and propionate concentrations. Acetate does not alter Aicda and Prdm1 expression, CSR or plasma cell differentiation. a, C57BL/6 mice, after weaning, were fed a fiber or no-fiber diet, and given SCFA-water (SCFAs) or plain water (Nil) starting at the age of 5 weeks. Concentrations of butyrate and propionate in the feces, as well as acetate, butyrate and propionate in the spleen, colon and mesenteric lymph nodes were measured by mass spectrometry 21 days later. Fecal and spleen SCFA data are means and SE from 3 mice in each group. Colon SCFA data are means and SE from two mice in each group. MLN SCFA data are from pooled samples of five mice of each group. b,c, Mouse B cells were stimulated with LPS plus IL-4, in the presence of increased concentration of acetate (0, 1250, 2500 or 5000 µM). The expression of Aicda and Prdm1 transcripts was analyzed 72 h post stimulation by qRT-PCR and normalized to Gapdh transcripts. Data are from three independent experiments (mean and SE) (b). The proportions of IgG1 + B cells and CD138 + plasmablasts/plasma cells were analyzed 96 h post stimulation by flow cytometry. Data are one representative of three independent experiments yielding comparable results (c). d, Gating strategy to analyze class-switched B cells and plasma cells in in vitro stimulated cells presented on (c). The same strategy was used for similar analysis presented on Fig. 7b ,d-f, 5a-d,f and Supplementary Fig. 6a ,b, 9a, 10c,d and 11b. The source data are provided in a Source Data file. Fig.  1e . The same strategy was used for similar analysis presented in Fig. 4h . b. Gating strategy to analyze intracellular AID expression presented in Fig. 2b . The same strategy was used for similar analysis presented on Fig. 4b, 10d and Supplementary Fig. 13c . c, Gating strategy to analyze fecal bacteria-bound antibodies presented in Fig. 2d,e. d , Gating strategy to analyze intracellular AID and Blimp1 expression presented in Fig. 3h . e, Gating strategy to analyze ex vivo classswitched B cells and plasma cells presented in Fig. 4c . GC formation. a,b , C57BL/6 mice fed fiber diet were given SCFA-water (SCFAs) or plain water (Nil) starting at the age of 5 weeks and injected with NP 16 -CGG (in alum) at the age of 8 weeks. The mice were sacrificed 10 days post-injection. Proportions of CD19 + B cells, CD3 + T cells, CD4 + and CD8 + T cells, proliferating B cells (BrdU-stained CD19 + B cells) and viable (7-AAD − ) CD19 + B cells in the spleen were analyzed by flow cytometry (a). GCs were visualized by fluorescent microscopy (B220, green; GL-7, orange) (b). c, Tcrb -/-Tcrd -/mice fed fiber diet were given SCFA-water or plain water starting at the age of 5 weeks and injected NP-LPS (in PBS) at the age of 8 weeks. GCs were visualized by fluorescent microscopy (B220, green; GL-7, orange) and H&E staining 10 days post-injection. d, Mouse and human B cells were stimulated with LPS plus IL-4 or CD154 plus IL-4 and IL-21, respectively, for 96 h, in the presence of nil, butyrate (500 µM), propionate (2000 µM) or butyrate (500 µM) plus propionate (2000 µM), and analyzed for viable (7-AAD − ) CD19 + B cells by flow cytometry. Data are one representative of three independent experiments yielding comparable results. a, Gating strategy to analyze ex vivo B cell proliferation and T cells presented on Supplementary Fig. 3a. e, Gating strategy for (a) . f, Gating strategy for (d). Scale bar = 100 µm.
. SCFAs dampen SHM in the T-independent antibody response to NP-LPS in Tcrb -/-Tcrd -/mice. Tcrb -/-Tcrd -/mice fed fiber diet were given SCFA-water (SCFAs) or plain water (Nil) starting at the age of 5 weeks and injected with NP-LPS (in PBS) at the age of 8 weeks. The mice were boost-injected 21 days later with NP-LPS (in PBS). Somatic point-mutations were analyzed in the V 186.2 region of V 186.2 DJ H -Cg3 (a,b) and V 186.2 DJ H -Cg2b (c,d) transcripts amplified from spleen B cells 7 days after the boost injection. Pie charts depict the proportions of sequences carrying different numbers of point-mutations over the 294 bp V 186.2 segment. Listed below the pie charts is the overall mutation frequency (change/base). Donut charts depict the spectrum of point-mutations (a,c) . Histograms depict frequencies of silent and replacement mutations in FR and CDR regions (b,d) . Data are from three pairs of fiber fed mice given SCFA-water and plain-water. The source data are provided in a Source Data file. Figure 6 . Butyrate and propionate inhibit CSR in a dose-dependent fashion. Mouse B cells were stimulated for 96 h with LPS plus IL-4, LPS plus IL-5, TGF-b, anti-d mAb-dextran and RA, in the presence of nil, butyrate (50, 100, 250 or 500 µM) or propionate (250, 500, 1000 or 2000 µM). a,b, The proportions of IgG1 + and IgA + B cells were analyzed by flow cytometry. Data are one representative of three independent experiments yielding comparable results. c,d, IgG1 and IgA titers in culture fluids as analyzed by specific ELISAs. Data are from three independent experiments (mean and SE). *p < 0.05, **p < 0.01, ***p < 0.001 (unpaired t-test) . . The source data are provided in a Source Data file. Figure 7 . Gating strategy for flow cytometry analysis. a, Gating strategy to analyze intracellular intracellular CD19 + IgE + B cells presented on Fig. 5e . b, Gating strategy to analyze CFSE signal in B cells presented on Fig. 5g . c, Gating strategy to analyze intracellular AID expression in in vitro stimulated B cells presented on Fig. 5k . d, Gating strategy to analyze class-switched human B cells and plasma cells presented on Fig. 6a,b . e, Gating strategy to analyze IgA+ CH12 B cells presented on Fig. 9f . f, Gating strategy to analyze class-switched plasmablasts presented on Supplementary Fig. 13e . Figure 13 . SCFAs reduce autoantibody response and autoimmunity in lupus-prone NZB/W F1 mice. Female NZB/W F1 mice fed fiber diet were given SCFA-water (SCFAs) or plain water (Nil) starting at the age of 14 weeks and sacrificed at 26 weeks of age. a, Titers of circulating anti-dsDNA IgM, and anti-dsDNA, anti-RNP/Sm, anti-histone and anti-RNA IgG1 and IgG2a (relative units, RU), as analyzed by specific ELISAs. Each symbol represents an individual mouse (n = 5 per group). *p < 0.05, **p < 0.01, ns: not significant (unpaired t-test). b, ANA visualized by indirect immunofluorescence on HEp-2 cells that were incubated with sera (1:400 dilution) from the NZB/WF1 mice using FITC-labeled rat mAbs to mouse IgG and IgG2a. Data are from one of 3 independent experiments yielding comparable results. c, AID and Blimp-1 expression as analyzed by intracellular staining followed by flow cytometry. d, Spleen surface IgG1, IgG2a, IgG2b and IgG3 B cells, and e, intracellular CD19 low/neg CD138 + , CD138 + IgG1 + , CD138 + IgG2a + , CD138 + IgG2b + , and CD138 + IgG3 + plasmablasts/plasma cells as analyzed by flow cytometry. Data are one representative of 3 independent experiments yielding comparable results. f, Kidney sections stained with H&E (right panels), and kidney sections stained with FITC-labeled rat mAbs to mouse IgG (right panels). Data are one representative of 3 independent experiments. Scale bar = 20 µm (b) or 100 µm (f) . The source data are provided in a Source Data file. Figure 14 . Dose-dependent modulation of Aicda and Prdm1 expression, CSR, SHM and plasma cell differentiation by SCFAs. SCFAs butyrate and propionate modulate B cell functions through HDAC inhibition activity, which leads to increased histone acetylation of many genes, including the host genes of select miRNAs targeting Aicda or Prdm1. While Aicdaand Prdm1-targeting miRNAs induced by SCFAs inhibits Aicda and Prdm1 in a dose-dependent fashion over a wide physiological SCFAs range, the Aicdaand Prdm1-targeting miRNAs-mediated inhibition of Aicda expression by low-dose SCFAs is not robust enough to override the enhancement of CSR/SHM resulting from increased SCFAs-mediated histone acetylation and germline I H -C H transcription. As for Prdm1, low-dose SCFAs merely are not sufficient to significantly dampen this gene expression, and, therefore, Blimp1 expression and plasma cell differentiation. 
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